daily hGH

Phase 3Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

daily hGH is one of 37 small molecule programs targeting Small for gestational age. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small for Gestational AgeActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

Small for Gestational AgePhase 2

Active, not recruiting

Growth Hormone DeficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Growth Hormone Deficiency

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Approved

24 2

Nutropin AQ

Roche

Approved

1 3

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

5 4

Saizen

Merck & Co.

Phase 3

3 5

PEG-Somatropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

8 6

Norditropin

Novo Nordisk

Phase 3

2 7

Macrilen

AAEterna Zentaris

Phase 3

1 8

Genotropin

Pfizer

Phase 2

6 9

LUM-201

LLumos Pharma

Phase 3

5 10

Human Growth Hormone

AAscendis Pharma A/S

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Small for Gestational Age

NCT07260500

Clinical

Trials by Indication[1]

Small for gestational age1 trial

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT07260500·72 enrolled

Growth Hormone Deficiency1 trial

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

Unknown status·VVisen Pharmaceuticals (Shanghai) Co., Ltd.·Phase 3·NCT04326374·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for daily hGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — daily hGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for daily hGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

daily hGH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Small for gestational age1 trial

Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Related News